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Abstract
MicroRNA-125b expression is modulated in macrophages in response to stimulatory cues. Here
we report a functional role of miR-125b in macrophages. We found that miR-125b is enriched in
macrophages compared to lymphoid cells and whole immune tissues. Enforced expression of
miR-125b drives macrophages to adapt an activated morphology that is accompanied by increased
co-stimulatory factor expression and elevated responsiveness to interferon gamma, while anti-
miR-125b treatment decreases CD80 surface expression. To determine whether these alterations in
cell signaling, gene expression and morphology have functional consequences, we examined the
ability of macrophages with enhanced miR-125b expression to present antigens and found that
they better stimulate T cell activation than control macrophages. Further indicating increased
function, these macrophages were more effective at killing EL4 tumor cells in vitro and in vivo.
Moreover, miR-125b repressed IRF4 and IRF4 knockdown in macrophages mimicked the
miR-125b overexpression phenotype. In summary, our evidence suggests that miR-125b is at least
partly responsible for generating the activated nature of macrophages, at least partially by reducing
IRF4 levels, and potentiates the functional role of macrophages in inducing immune responses.
INTRODUCTION
The mammalian innate immune system provides a critical first line of defense against
pathogens. Macrophages are key components of this system, acting to release cytokines, kill
pathogens directly and present antigens to the adaptive immune system. The macrophage
surface contains sensing proteins, like Toll-like receptors and interferon gamma receptor
that, when engaged, lead to a rapid differentiation event termed “activation”, where the cell
transforms from relative quiescence to an effector state characterized by far-heightened
microbicidal ability. Macrophages also carry co-stimulatory proteins such as CD80 and
CD86 for interacting with T cells, thus bridging innate immunity to adaptive immunity (1,
2).
Recently microRNAs have been shown to be important mediators of the macrophage
activation process. MicroRNAs-155, 146, 147, 9 and 21 are induced by ligands of the Toll-
like receptors (TLRs) (3, 4). These microRNAs, in turn, inhibit expression of protein in the
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inflammatory signaling cascade, thus modulating immunity through feedback regulation (3,
4). MiR-125b, a homologue of the C. elegans microRNA lin-4, has been shown to be
decreased in macrophages in response to TLR4 signaling (5–7).
We and others found that miR-125b is enriched in hematopoietic stem cells and that
increased miR-125b enhances hematopoietic engraftment (8, 9). Further increased levels of
miR-125b cause an aggressive myeloproliferative disorder that leads to leukemia (8). Here
we examine the role miR-125b plays in regulating macrophage activation. We find that
macrophages express a particularly high concentration of miR-125b. When miR-125b is
overexpressed in macrophages, it enhances surface activation markers both basally and in
response to interferon gamma. By contrast, treatment of RAW264.7 macrophages with anti-
miR-125b causes them to express decreased surface CD80 both basally and in response to
interferon gamma. We demonstrate that macrophages expressing increased miR-125b
become more potent stimulators of immune responses as shown by increased antigen-
specific T cell activation and anti-tumor immunity. Lastly, we find that IRF4 is an important
target of miR-125b in macrophages and that IRF4 knockdown mimics the miR-125b
overexpression phenotype.
METHODS
Cell Culture
293T cells, RAW264.7 cells and BMMs were cultured at 37°C with 5% CO2 in DMEM
supplemented with 10% FBS, 100 units/ml penicillin and 100 units/ml streptomycin. For
IFNγ treatment, cells were treated overnight with 200 units/ml of recombinant mouse IFNγ
(eBioscience).
Mice
C57Bl/6 and OTI Ovalbumin TCR-transgenic Balb/c mice were bred in the Caltech Office
of Laboratory Animal Resources (OLAR) facility or purchased from Jackson Laboratories.
The Caltech Institutional Animal Care and Use Committee (IACUC) approved all mouse
experimental protocols.
Isolation of Immune Cells and Tissues
T cells and B cells were purified from the spleens of C57Bl/6 mice using magnetic beads
(Miltenyi). Peritoneal macrophages were isolated four days after injecting mice with 3%
Thyoglycollate.
DNA Constructs
The MG, MGP, MG-125b-1 and MGP-125b-1 vector systems have been described
previously (10–12). The human miR-125b-1 sequence was also cloned into the pcDNA3
vector downstream of the CMV promoter. The IRF4 shRNA sequence was predicted and
cloned into MGP as described previously (11, 13). NC1 is a negative control shRNA
sequence predicted not to target any protein coding genes in the mouse genome (Invitrogen).
For reporter assays, pMIR-REPORT vector (Ambion) containing Picalm and Cutl1 3’UTRs
were constructed previously (10). A 3 kb region of the human IRF4 3’UTR, which includes
the miR-125b putative binding site, was cloned into pMIR-REPORT downstream of
luciferase. A positive control 2mer containing two tandem sites complementary to miR-125b
was also cloned. Primer sequences are listed in Table S1.
Chaudhuri et al. Page 2
J Immunol. Author manuscript; available in PMC 2012 November 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Retrovirally Transduced Bone Marrow Derived Macrophages
To generate retrovirus for infecting bone marrow, 293T cells were transfected with pCL-Eco
and MG, MGP, MG-125b-1 or MGP-125b-1 vectors. After 36 h, 10 ug/ml polybrene
(Millipore) was added to retrovirus-containing culture supernatant, which was used to spin-
infect bone marrow from C57Bl/6 mice. Cells were counted and 1 million were plated per
well in a 6 well plate with 10 ng/ml M-CSF (eBioscience), and differentiated for 6 days to
yield retrovirally transduced BMMs (12).
Stable Cell Lines
RAW264.7 cells were stably transduced with VSV-G-pseudotyped MGP or MGP-125b-1
retrovirus and puromycin selection was subsequently performed as described previously
(11).
Electroporation of Anti-miRs
RAW264.7 cells were co-electroporated with anti-miR-125b or a mismatched control
(Regulus Therapeutics) and pmaxGFP vector (Lonza) using an Amaxa Nucleofector. 36
hours post-electroporation, GFP positive cells were analyzed by FACS. Anti-miR-125b or
mismatched control compound were chimeric 2′-fluoro/2′-O-methoxyethyl-modified
oligonucleotides with a completely modified phosphorothioate backbone (14) (Regulus
Therapeutics). The exact chemistry is available on request.
T-cell Macrophage Co-Culture
50,000 BMMs stably expressing either MG or MG-125b-1 were co-cultured with 150,000 T
cells harvested from OTI Ova TCR-transgenic Balb/c mouse in a 48 well flat bottom plate in
the absence or presence of ovalbumin protein. Flow cytometry and ELISAs to assess T cell
activation were performed 72 hours later. ELISAs were performed with an IL-2 detection kit
from eBioscience and carried out according to the manufacturer’s instructions.
EL4 Tumor Cell Experiments
500,000 BMMs stably expressing either MG or MG-125b-1 were generated as described
above in 6 well plates. One million EL4-Fluc cells were added to each well supplemented
with 20 ng/ml LPS. EL4-Fluc apoptosis was measured 94 hours later by staining cells in
suspension with AnnexinV antibody (BD Pharmingen). For the in vivo experiments, 2
million EL4-Fluc cells were co-injected with 400,000 BMMs subcutaneously into albino
C57Bl/6 mice. Mice were closely monitored over the next 12 days. Tumor luminescence
was measured using a Xenogen imager. At the experimental endpoint, animals were
euthanized and tumors were removed and weighed. Tumor surface area was assessed using a
caliper— tumor length and width were measured in cm, and the product was taken to
determine surface area.
Sequence Alignment
The miR-125b seed region and IRF4 3’UTR sequences from human (Homo sapien), mouse
(Mus musculus), cat (Felis catus) and armadillo (Dasypus novemcinctus) were obtained and
aligned using Targetscan (15–17).
Luciferase Reporter Assay
293T cells were co-transfected with pcDNA-125b, β-gal expression vector, and the pMIR-
REPORT vectors containing 3’UTRs of Cutl1, Picalm, IRF4 or 2mer. The luciferase activity
was quantified 48 hours later and normalized to β-gal activity as previously described (11,
13).
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RNA Preparation and Quantification
RNA was isolated using TRIzol (Invitrogen), RNEasy (Qiagen) or miRNEasy (Qiagen) as
per manufacturer’s instructions. Quantitative real-type PCR (qPCR) was conducted using a
7300 Real-time PCR machine (Applied Biosystems) or a Realplex Real-time PCR machine
(Eppendorf). SYBR green was used to assay IRF4 and L32 expression. PCR with previously
published primer sequences for mouse pri-miR-125b-1 and pri-miR-125b-2 were used to
assay levels of miR-125b primary transcripts (18). Taqman based qPCR was conducted to
assay miR-125b, miR-125a and snoRNA-202 (Applied Biosystems). Primer sequences are
listed in Table S1.
Flow Cytometry
Cells were stained with the following fluorophore-conjugated antibodies: CD80, CD86,
CD40 (Biolegend); MHC II (eBioscience); AnnexinV (BD Pharmingen). Cell surface
receptors were measured using a FACSCalibur (Becton Dickinson) and all data was
analyzed with FloJo (Treestar). Data was gated on GFP positive events when retrovirally
transduced cells were analyzed.
RESULTS
MiR-125b expression is enriched in macrophages
To investigate the expression of miR-125b in different immune cells and tissues, we
harvested RNA from total splenocytes, thymocytes, splenic T cells, splenic B cells, and
peritoneal macrophages from C57Bl/6 mice. Levels of miR-125b were assessed by reverse
transcription followed by quantitative PCR. The expression of miR-125b was much higher
in macrophages compared to the other immune cells and tissues (Fig. 1A). Within
macrophages, miR-125b levels were also significantly higher than its homologue, miR-125a,
indicating that miR-125b is the dominant isoform in these cells (Fig. S1). Also, miR-125b is
expressed from two loci in the mouse genome, each encoding a different primary transcript.
We performed RT-PCR for each of these primary transcripts and determined that
macrophages express primarily miR-125b-1 (Fig. 1B). Because miR-125b-1 is enriched in
macrophages, we set out to determine the functional role of miR-125b-1 (referred from here
on as miR-125b) in these cells.
Enforced expression of miR-125b enhances macrophage activation status
To examine the response of macrophages to miR-125b, we utilized a miR-125b over-
expression system based on the MG vector (MG-miR-125b), which was originally derived
from the murine stem cell virus (10) (Fig. 2A). Bone marrow cells isolated from C57Bl/6
mice were spin-infected with either MG-miR-125b or MG control vector. These cells were
then differentiated into bone marrow derived macrophages (BMMs) by treatment with
macrophage-colony stimulating factor (M-CSF). Using this system, miR-125b was over-
expressed 15-fold above endogenous levels in BMMs (Fig. 2B). Interestingly, miR-125b
over-expressing BMMs acquired a spread morphology with extensive pseudopods that
resembled activated macrophages (Fig. 2C). We performed flow cytometric analyses and
observed increased expression of MHCII and the co-stimulatory molecules CD40, CD86
and CD80 in these macrophages, indicating that these cells were indeed more activated (fig.
2D). Ectopic expression of miR-125b in RAW264.7 macrophages gave similar results (Fig.
S2 A), further emphasizing that this microRNA promotes activation of macrophages.
MiR-125b increases macrophage response to interferon gamma
Next, we assessed the effect of miR-125b on the responsiveness of macrophages by
stimulating these cells with interferon gamma (IFNγ). IFNγ treatment increased the
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expression of MHCII, CD40, CD86, and CD80 activation markers in control macrophages
(Fig. 3A) while miR-125b over-expressing macrophages expressed significantly higher
levels of these markers (Fig. 3A). Similar results were obtained in RAW264.7 macrophages
with enforced miR-125b expression (Fig. S2 A).
To examine whether reducing the concentration of miR-125b had an effect inverse to that of
overexpression. RAW264.7 macrophages were treated with synthetic antisense
oligonucleotides (anti-miRs) and surface CD80 levels were monitored as an indication of the
activation status of the cells. Anti-miR125b did cause a reduction of both basal and IFNγ
induced levels of CD80 compared to cells treated with a control anti-miR (Fig3 B). Thus,
miR-125b appears to control CD80 expression in macrophages under normal, physiological
conditions.
A likely reason for the heightened response to IFNγ in miR-125b-treated cells could be an
increased expression of the interferon gamma receptor (IFNγR). Indeed, miR-125b over-
expressing BMMs (Fig. 3C) and RAW264.7 macrophages (Fig. S2 B) had significantly
higher levels of the receptor. Thus, in addition to potentiating macrophage activation,
miR-125b promotes enhanced macrophage responsiveness to IFNγ and increases surface
expression of its cognate receptor.
MiR-125b enhances macrophage-mediated function
Because we found that miR-125b drove macrophages to adopt an elevated activation status
and become more responsive to stimulatory cues, we examined whether miR-125b would
also potentiate macrophage-mediated immune function. To this end, we investigated
whether miR-125b would increase the ability of macrophages to present antigens and induce
activation of T cells. MiR-125b over-expressing macrophages were co-cultured with
transgenic T cells that express a chicken ovalbumin-specific T cell receptor (OT1) in the
presence of ovalbumin. Indeed, compared to control macrophages, miR-125b over-
expressing cells were more effective at inducing T cell activation, which was indicated by
increased CD25 expression and IL-2 secretion by the T cells in response to ovalbumin (Fig.
4A). Thus, enforced expression of miR-125b led to an elevated ability of macrophages to act
as effective antigen presenting cells for stimulation of T cell responses.
In addition to serving as antigen presenting cells, another major function of macrophages is
to eliminate aberrant cells, such as tumor cells. We therefore assessed whether miR-125b-
stimulated macrophages were more effective at killing tumor cells. We used the EL4-Fluc
thymoma tumor line (19), which was engineered to express luciferase, and co-cultured these
cells with either control macrophages or macrophages over-expressing miR-125b.
Consistent with augmented function, miR-125b expressing macrophages were better at
inducing apoptosis of EL4-Fluc cells (Fig. 4B). Macrophages exposed to LPS gained the
ability to induce apoptosis of EL4-Fluc cells, with miR-125b-overexpressing macrophages
having superior effectiveness (Fig. 4B). To test whether miR-125b levels in macrophages
affect tumor killing in vivo, we subcutaneously co-injected into mice equal numbers of LPS-
activated control or LPS-activated miR-125b overexpressing macrophages with EL4-Fluc
cells and tracked growth of the resulting tumor by measuring tumor surface area over time.
Since EL4-Fluc cells were engineered to express luciferase, we also monitored tumor
growth by measuring luminescence in vivo. Consistent with our in vitro data, macrophages
with miR-125b ectopic expression suppressed the ability of EL4 cells to expand in vivo (Fig.
4C). At the endpoint of the experiment on day 12, animals injected with MG-125b
macrophages had smaller EL4-derived tumors that were significantly less luminescent than
those injected with control macrophages (Fig. 4 D–E). Thus, miR-125b expression in
macrophages appears to aid them in preventing the expansion of tumorigenic cells, further
demonstrating that miR-125b enhances macrophage function.
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IRF4 is a miR-125b target in macrophages
To identify targets regulated by miR-125b that modulate macrophage activation, we used
TargetScan 5.1 to identify transcripts in the mouse genome that contain conserved putative
miR-125b binding sites in their 3’ untranslated regions (UTRs). Among these genes, the
3’UTR of IRF4 harbored a conserved miR-125b binding site (Fig. 5A) and has been
previously validated as a miR-125b target in B cell lines (20–23). We found that miR-125b
indeed represses via the 3’UTR of IRF4 (Fig. 5B) and that miR-125b inhibits IRF4
expression in macrophages (Fig. 5C). Next, using the MGP retroviral vector system (11), we
knocked down the expression of IRF4 using RNAi (Fig. 5D) and examined the effect in
macrophages. MGP-125b led to a 6-fold increase in miR-125b in BMMs. Similar to
miR-125b overexpression, decreased IRF4 expression resulted in increased surface
expression of MHCII, CD40, CD86, CD80 and IFNγR (Fig 5E). Thus IRF4 knockdown in
macrophages enhances activation, mimicking the miR-125b overexpression phenotype. This
data is consistent with previous reports demonstrating that IRF4 is a negative regulator of
macrophage pro-inflammatory pathways.(21, 24) Collectively, our data suggests that IRF4 is
a primary target of miR-125b in regulating macrophage activation.
DISCUSSION
In this study, we demonstrate that miR-125b is enriched in macrophages and that further
elevation of miR-125b promotes greater activation, IFNγ response, and immune function in
these cells. We also performed loss-of-function studies using synthetic antisense
oligonucleotides designed to inhibit miR-125b, and found that this anti-miR-125b compound
effectively decreased CD80 levels, supporting a physiological role for miR-125b in
macrophage activation. Other groups have reported that miR-125b levels decrease in
macrophages 3 hours post-inflammatory stimulation (5, 7). Thus, decreasing miR-125b may
serve as a natural mechanism to limit the inflammatory response. In our studies, miR-125b
overexpression also promoted the ability of macrophages to present antigen and induce T
cell activation, demonstrating that miR-125b can enhance the macrophage’s role in
mediating adaptive immunity. The increase in activated T cells would in theory result in
more secretion of IFNγ, which in turn would further magnify the activation status of
miR-125b-expressing macrophages. In this way, by affecting macrophage function alone,
miR-125b could amplify both innate and adaptive immune responses by orchestrating
positive feedback loops between macrophages and T cells.
In B cells, miR-125b inhibits differentiation of germinal center B cells into plasma cells, and
does so via repression of the transcription factors IRF4 and BLIMP1 (23, 25). Recently,
IRF4 was shown in B cell lines to regulate levels of BIC/miR-155, an interaction that might
be important in leukemic transformation (26). IRF4, a member of the Interferon Response
Factor family of transcription factors, also has important functions in macrophages where it
acts as an inhibitor of the inflammatory response (21, 24). We demonstrate here that IRF4 is
a target of miR-125b and that IRF4 knockdown mimics the miR-125b mediated activation
phenotype in macrophages. Thus, miR-125b’s ability to potentiate macrophage activation is
consistent with previously demonstrated roles of its target, IRF4, to inhibit pro-inflammatory
macrophage polarization (27).
MiR-125b is upregulated in certain leukemias and downregulated in many non-
hematopoietic solid cancers (12, 28–38). We have shown here that increased miR-125b
expression in tumor macrophages slows tumor growth. Our data suggests that
supplementing tumor macrophages with miR-125b may be a useful strategy for treating
certain cancers. Future studies should aim to better understand the physiological and
pathological mechanisms underlying control of miR-125b expression in macrophages.
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BLIMP1 B lymphocyte-induced maturation protein 1
Chaudhuri et al. Page 9
J Immunol. Author manuscript; available in PMC 2012 November 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 1.
MiR-125b expression is enriched in macrophages. A) Relative expression of miR-125b in
immune tissues and cells assessed by quantitative PCR. Data represents the mean with SEM
of 3 biological replicates per group. B) Expression of the miR-125b primary transcripts,
pri-125b-1 and pri-125b-2, in bone marrow derived macrophages (BMMs). Data is
representative of two independent experiments.
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Figure 2.
MiR-125b enhances basal macrophage activation. A) Retroviral vector design for over-
expression of miR-125b-1. B) Relative expression of miR-125b in BMMs after transduction
with MG or MG-miR-125b expressing vector. C) Morphology of control MG or miR-125b
over-expressing BMMs. Data represent five independent experiments. D) Geometric mean
fluorescence (GMF) of MHCII, CD40, CD86 and CD80 are shown. Representative plots
obtained from flow cytrometric analyses are also shown for each marker. Data is the mean
with SEM of 3–5 samples per group and is representative of two independent experiments.
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Figure 3.
MiR-125b increases macrophage response to IFNγ. A) Surface expression of MHCII, CD40,
CD86, and CD80 in response to media alone or IFNγ. A representative flow cytometric plot
of the IFNγ treated samples is shown for each factor. B) Raw264.7 macrophages
electroporated with control (NC) or anti-miR-125b were subjected to flow cytometry for the
surface expression of CD80. A representative FACS plot of the media-treated samples
shown. C) Surface expression of IFNγR in control (MG) versus miR-125b over-expressing
macrophages. A representative FACS plot is shown. All data shown represents the mean
expressed with SEM of three samples per group and is representative of two independent
experiments.
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Figure 4.
MiR-125b enhances macrophage function. A) BMMs expressing the vectors MG or
MG-125b were co-cultured with ovalbumin-specific OT1 T cells with or without ovalbumin
for 72 hours. The percent CD8+CD25+ T cells are shown in the left panel. Concentration of
IL-2 (pg/ml) produced by the T cells in the supernatant is shown in the right panel. Data
represents the mean with SEM of 3 biological replicates per group. B) The percent
AnnexinV+ EL4-Fluc cells after 94 hours of co-culture with control or miR-125 over-
expressing macrophages in the presence of media alone or lipopolysaccharide (LPS). A
representative flow cytometric plot of the LPS-treated group is shown. Data is expressed in
mean with SEM of 1–3 experimental samples per group. C–E) EL4-Fluc cells were
subcutaneously co-injected with LPS-activated control or miR-125b over-expressing
macrophages into albino C57Bl/6 mice. Tumor surface area in cm2 was monitored from day
9–12 (C). The relative intensity of luminescence (D) and weight (E) of the EL4 tumors were
measured on day 12. Data represents the mean plotted with SEM of eight mice per group.
Representative of two independent experiments.
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Figure 5.
IRF4 is a target of miR-125b in macrophages. A) IRF4 contains a conserved miR-125b
target site. B) Luciferase reporters carrying the 3’UTR of IRF4, Picalm (negative control),
Cutl1 (negative control) or 2mer (positive control) were co-transfected into 293T cells with
β-gal reporter and +/− miR-125b. The relative luciferase activity of each reporter in the
presence of miR-125b is shown relative to the no microRNA control. C) RAW264.7
macrophages were transduced with either a control (MGP) or miR-125b expressing vector,
or with D) control (NC1) or IRF4 shRNA expressing vector. RNA was harvested and L32-
normalized IRF4 levels were determined by qPCR. E) BMMs expressing MGP, MGP-125b,
or shRNA against IRF4 were measured for surface expression of the activation markers
MHCII, CD40, CD86, CD80 and IFNγR. Geometric Mean Fluorescence (GMF) measured
by flow cytometry is shown. All data represents the mean with SEM of 3 samples per group
and is representative of two independent experiments.
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